Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Oric Pharmaceuticals (ORIC) Enterprise Value (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Enterprise Value readings, the most recent being -$281.9 million for Q1 2026.

  • Quarterly Enterprise Value fell 38.39% to -$281.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$281.9 million through Mar 2026, down 38.39% year-over-year, with the annual reading at -$281.5 million for FY2025, 9.97% down from the prior year.
  • Enterprise Value hit -$281.9 million in Q1 2026 for Oric Pharmaceuticals, roughly flat from -$281.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$189.6 million in Q1 2023 and bottomed at -$316.8 million in Q1 2024.
  • Average Enterprise Value over 5 years is -$248.2 million, with a median of -$256.0 million recorded in 2024.
  • The largest annual shift saw Enterprise Value tumbled 67.05% in 2024 before it surged 35.69% in 2025.
  • Oric Pharmaceuticals' Enterprise Value stood at -$206.3 million in 2022, then fell by 0.93% to -$208.2 million in 2023, then decreased by 22.95% to -$256.0 million in 2024, then fell by 9.97% to -$281.5 million in 2025, then dropped by 0.16% to -$281.9 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Enterprise Value are -$281.9 million (Q1 2026), -$281.5 million (Q4 2025), and -$287.1 million (Q3 2025).